We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Ovoca Bio Plc | LSE:OVB | London | Ordinary Share | IE00B4XVDC01 | EUR0.125 (CDI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.825 | 0.75 | 0.90 | 0.825 | 0.825 | 0.83 | 119,941 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 1.46M | -5.61M | -0.0688 | -0.12 | 668.82k |
Date | Subject | Author | Discuss |
---|---|---|---|
22/2/2022 16:16 | DAVEY the onloy MM on 21p, if they move up we are off a lot higher in my opinion. | mickinvest | |
22/2/2022 16:16 | This looks like going higher - | tomboyb | |
22/2/2022 16:12 | The approved manufacturing site for Orenetide will be operated by two reputable pharmaceutical manufacturers - Nativa and OncoTarget, with commercial production of Orenetide expected to start in Spring 2022. Ovoca Bio is currently in discussions with a number of partners to explore a potential license partnerships for sales of Orenetide on the Russian market. Spring 2022 folk, it's happening. | mickinvest | |
22/2/2022 16:09 | mm, its on the rise again. decisions, decisions! | abbynat | |
22/2/2022 16:08 | agree to you all. must admit i was busy looking elsewhere so i missed the rns, at 50% i would have sold so maybe i'll hang on again, yet again.seems to be the story with some of mine recently. i'm trying to get rid of some of the small fish that don't want to swim far in my modest portfolio. gla. | abbynat | |
22/2/2022 16:06 | I don't think many of the pump and dumpers got in on this, be lucky if there are 100k trades under 16p after the news came out. | mickinvest | |
22/2/2022 16:01 | I'm telling you they are really valuing this wrong atm. Perhaps not the best of days for Russian news but with the cash in the bank, this deal and major trials in Australia this is a 50p stock in the making. You go and look at what valuations other Bio's have with similar | dave4545 | |
22/2/2022 16:00 | There is, however a problem if you say you will do something and do the converse - That is deceit - Back to OVB, the news is excellent - and there is more news in the pipeline - | tomboyb | |
22/2/2022 15:59 | I think intraday Rns's should be abolished Either 7am or 4.30pm If they have this news to announce wait until the market closes Do not let those parasite conmen get in cheaper than us when we have held 30 months ffs. I do not know why companies do this | dave4545 | |
22/2/2022 15:59 | Them numptys play with pocket money they aint moving any share | gooner1886 | |
22/2/2022 15:54 | However, OVB this is excellent news - HIGHLIGHTED BIT - | tomboyb | |
22/2/2022 15:52 | Dave - In terms of traders, I think you have to trade in and out of this market otherwise you will be left behind - Took a trade at THG today and almost skimmed 10% - Look at it now, back down again - Sentiment is not there yet in these markets - | tomboyb | |
22/2/2022 15:51 | Look at the trades just after, the usual suspect pump and dump merchants who have all sold already Worth at least double the current price after that news | dave4545 | |
22/2/2022 15:50 | Look at the trades before it - Selling at 10pish - | tomboyb | |
22/2/2022 15:48 | Nice day to announce it :-) | mickinvest | |
22/2/2022 15:45 | Kirill Golovanov, Chief Executive Officer of Ovoca Bio plc, said: "Marketing authorisation approval for Orenetide in Russia is a welcome development for HSDD patients and a major step that provides Ovoca Bio with a solid foundation to engage in distribution agreements for commercialisation of the treatment in Russia. We are currently in several partnership discussions and will provide an update on our progress in due course. We are also continuing our development programme for Orenetide in a wider international markets which are Ovoca's principal target. Phase II dose-ranging study assessing Orenetide being conducted in Australia and New Zealand has reached over 70% of participants' enrolment, paving the way for Ovoca Bio target to reach 100% ennrolment of participants by mid-2022." | tomboyb | |
22/2/2022 15:42 | shame they let the pump and dump merchants in like toptradersadvfn he's already dumped | dave4545 | |
22/2/2022 15:39 | wow you day traders are so fast | dave4545 | |
22/2/2022 15:36 | excellent - | tomboyb | |
21/2/2022 07:44 | I wonder if the rns feed for OVB is broken? | jibba jabber | |
17/2/2022 07:06 | I can't keep up with the newsflow here, said no one. | jibba jabber |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions